Associations - Alunbrig (brigatinib)

ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2
ALK translocation	Soft Tissue Sarcoma	ALK translocation	Soft Tissue Sarcoma	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2
ALK fusion	Lung Non-Squamous Non-Small Cell Cancer	ALK fusion	Lung Non-Squamous Non-Small Cell Cancer	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2
ALK positive	Lung Non-Small Cell Squamous Cancer	ALK positive	Lung Non-Small Cell Squamous Cancer	brigatinib Sensitive: C1 - Off-label brigatinib Sensitive : C1	brigatinib Sensitive: C1 - Off-label brigatinib Sensitive : C1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	brigatinib Sensitive: C2 – Inclusion Criteria brigatinib Sensitive : C2	brigatinib Sensitive: C2 – Inclusion Criteria brigatinib Sensitive : C2
ALK positive + ALK mutation	Non Small Cell Lung Cancer	ALK positive + ALK mutation	Non Small Cell Lung Cancer	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	cetuximab + brigatinib Sensitive: C3 – Early Trials cetuximab + brigatinib Sensitive : C3	cetuximab + brigatinib Sensitive: C3 – Early Trials cetuximab + brigatinib Sensitive : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	cetuximab + brigatinib Sensitive: C3 – Early Trials cetuximab + brigatinib Sensitive : C3	cetuximab + brigatinib Sensitive: C3 – Early Trials cetuximab + brigatinib Sensitive : C3
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3
ALK F1174V	Non Small Cell Lung Cancer	ALK F1174V	Non Small Cell Lung Cancer	brigatinib Resistant: C3 – Early Trials brigatinib Resistant : C3	brigatinib Resistant: C3 – Early Trials brigatinib Resistant : C3
ALK R1192P	Non Small Cell Lung Cancer	ALK R1192P	Non Small Cell Lung Cancer	brigatinib Resistant: C3 – Early Trials brigatinib Resistant : C3	brigatinib Resistant: C3 – Early Trials brigatinib Resistant : C3
ALK D1203N	Non Small Cell Lung Cancer	ALK D1203N	Non Small Cell Lung Cancer	brigatinib Resistant: C3 – Early Trials brigatinib Resistant : C3	brigatinib Resistant: C3 – Early Trials brigatinib Resistant : C3
ALK F1174L + ALK G1202R	Non Small Cell Lung Cancer	ALK F1174L + ALK G1202R	Non Small Cell Lung Cancer	brigatinib Resistant: C3 – Early Trials brigatinib Resistant : C3	brigatinib Resistant: C3 – Early Trials brigatinib Resistant : C3
EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G	Lung Adenocarcinoma	EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G	Lung Adenocarcinoma	cetuximab + brigatinib Sensitive: C3 – Early Trials cetuximab + brigatinib Sensitive : C3	cetuximab + brigatinib Sensitive: C3 – Early Trials cetuximab + brigatinib Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3
EGFR C797S	Lung Adenocarcinoma	EGFR C797S	Lung Adenocarcinoma	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3
EML4-ALK fusion + ALK positive	Non Small Cell Lung Cancer	EML4-ALK fusion + ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3
ALK positive	T Cell Non-Hodgkin Lymphoma	ALK positive	T Cell Non-Hodgkin Lymphoma	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3
TP53 mutation + ALK positive	Non Small Cell Lung Cancer	TP53 mutation + ALK positive	Non Small Cell Lung Cancer	brigatinib Resistant: C3 – Early Trials brigatinib Resistant : C3	brigatinib Resistant: C3 – Early Trials brigatinib Resistant : C3
EML4-ALK + ALK G1202R + LIPI-NTRK1	Lung Adenocarcinoma	EML4-ALK + ALK G1202R + LIPI-NTRK1	Lung Adenocarcinoma	brigatinib Resistant: C4 – Case Studies brigatinib Resistant : C4	brigatinib Resistant: C4 – Case Studies brigatinib Resistant : C4
EML4-ALK rearrangement	Non Small Cell Lung Cancer	EML4-ALK rearrangement	Non Small Cell Lung Cancer	brigatinib Sensitive: C4 – Case Studies brigatinib Sensitive : C4	brigatinib Sensitive: C4 – Case Studies brigatinib Sensitive : C4
ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	brigatinib Sensitive: C4 – Case Studies brigatinib Sensitive : C4	brigatinib Sensitive: C4 – Case Studies brigatinib Sensitive : C4
ATM G2695D	Non Small Cell Lung Cancer	ATM G2695D	Non Small Cell Lung Cancer	brigatinib Resistant: C4 – Case Studies brigatinib Resistant : C4	brigatinib Resistant: C4 – Case Studies brigatinib Resistant : C4
NF1 R2258Q	Non Small Cell Lung Cancer	NF1 R2258Q	Non Small Cell Lung Cancer	brigatinib Resistant: C4 – Case Studies brigatinib Resistant : C4	brigatinib Resistant: C4 – Case Studies brigatinib Resistant : C4
ROS1-CD74 fusion + TP53 K139N	Non Small Cell Lung Cancer	ROS1-CD74 fusion + TP53 K139N	Non Small Cell Lung Cancer	brigatinib Resistant: C4 – Case Studies brigatinib Resistant : C4	brigatinib Resistant: C4 – Case Studies brigatinib Resistant : C4
MET exon 14 mutation + KRAS G12A	Non Small Cell Lung Cancer	MET exon 14 mutation + KRAS G12A	Non Small Cell Lung Cancer	brigatinib Resistant: C4 – Case Studies brigatinib Resistant : C4	brigatinib Resistant: C4 – Case Studies brigatinib Resistant : C4
FGFR2 E250G	Non Small Cell Lung Cancer	FGFR2 E250G	Non Small Cell Lung Cancer	brigatinib Resistant: C4 – Case Studies brigatinib Resistant : C4	brigatinib Resistant: C4 – Case Studies brigatinib Resistant : C4

Alunbrig (brigatinib)

Associations
(50)

Associations
(50)

Alunbrig (brigatinib)

Associations(50)

Associations(50)

Associations
(50)

Associations
(50)